Aprea Therapeutics, Inc. APRE
0.52 USD +0.02 (+4.89%)
At closeNov 3, 2026, 7:49 PM EST
0.52 0.00 +0.70%
After hours · Nov 3, 7:49 PM ET
0.48 Day range 0.5166
0.449 52-week range 1.40
- YTD
- -39.62%
- 1 year
- -63.21%
- Market cap
- 6.48M
- Revenue (ttm)
- 1.28M
- EPS (ttm)
- -0.95
- Shares out
- 5.43M
- Forward P/E
- -3.08
- YTD return
- -39.62%
- 1-year return
- -63.21%
- Volume
- 63.81K
- Avg volume
- 309.13K
- Open
- 0.4875
- Previous close
- 0.491
- Day's range
- 0.48 – 0.5166
- 52-week range
- 0.449 – 1.40
- Beta
- 1.74
- Analysts
- Buy
- Price target
- 15.67 (+2942.1%)
- Earnings date
- Aug 12, 2024
2Y -3.4550 (-87.03%)
Key statistics
- Enterprise value
- -5.20M
- PEG ratio
- 0.00
- Price / sales
- 13.38
- Price / book
- 0.69
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 124.90%
- Free cash flow
- -9.36M
- Total cash
- 28.69M
- Total debt
- 0
- Return on equity
- -50.11%
- Short % of float
- 0.38%
- 50-day average
- 3.48
- 200-day average
- 4.17
Analyst view
Consensus: buy
Buy
Price target (mean) 15.67 +2942.1% upside
Now 0.515
- Target (low)
- 11.00
- Target (mean)
- 15.67
- Target (high)
- 20.00
Ratings (0m) 3 3 buy · 0 hold · 0 sell
- Strong buy2
- Buy1
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 12, 2024
Expected Aug 12, 2024. Consensus EPS estimate -0.57.
Financials — quick view
APRE Revenue — quarterly 0
APRE Net income — quarterly -3.59M
APRE EPS — quarterly -0.07
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 7, 2024 | Sep 1, 2024 | -0.75 | -0.64 | +0.11 | +14.67% |
| Aug 12, 2024 | Jun 1, 2024 | -0.64 | -0.58 | +0.06 | +9.38% |
| Aug 12, 2024 | Jun 1, 2024 | -0.64 | — | — | — |
| May 14, 2024 | Mar 1, 2024 | -0.78 | — | — | — |
| May 14, 2024 | Mar 1, 2024 | -0.78 | -0.67 | +0.11 | +14.10% |
| Mar 26, 2024 | Dec 1, 2023 | -0.56 | -0.92 | -0.36 | -64.29% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 17, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Nov 18, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Oct 24, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 13, 2024 | Wedbush | reit | Outperform | Outperform |
| Aug 12, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Jun 24, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
About Aprea Therapeutics, Inc.
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors. The company is also developing ATRN-1051 for the treatment of ovarian cancer; and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- aprea.com
News
Aprea Therapeutics to Host Pre-ESMO Virtual Panel on the State of WEE1 Inhibition in Precision Oncology 
Ladenburg Thalmann Initiates Coverage On Aprea Therapeutics with Buy Rating, Announces Price Target of $2 
12 Health Care Stocks Moving In Thursday's After-Market Session 
Aprea Therapeutics to Present at October Conferences 
Aprea Therapeutics Announces Abstract Featuring Updated Interim Results From The Ongoing Phase 1 ACESOT-1051 Study Of Its WEE1 Inhibitor APR-1051 In Patients With Advanced Solid Tumors Has Been Accepted For Oral Presentation At The Symposium On Molecular Targets And Cancer Therapeutics 
Aprea Therapeutics to Present Updated Interim Phase 1 Data on WEE1 Inhibitor APR-1051 in an Oral Presentation at 38th EORTC-NCI-AACR Symposium 
Aprea Therapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference 
Aprea Therapeutics Expands Current Patent Portfolio 
Aprea Therapeutics Announces Expansion of Intellectual Property Portfolio for Precision Oncology Programs - 12 Health Care Stocks Moving In Thursday's Intraday Session
Your note
Sign in to keep a note on APRE — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| DUEY MARC | Director | Sale | Oct 17, 2024 | 234,253 |
| GILAD OREN PH.D. | Chief Executive Officer | Purchase | Oct 22, 2024 | 335,195 |
| GRISSINGER MICHAEL J. | Director | Stock Award(Grant) | Jun 19, 2024 | 1,844 |
| HAMILL JOHN P | Chief Financial Officer | Purchase | Oct 10, 2024 | 19,368 |
| HENNEMAN JOHN BELL III | Director | Stock Award(Grant) | Jun 19, 2024 | 9,184 |
| MIRZA NADEEM Q. | Officer | Stock Award(Grant) | Apr 30, 2024 | 6,730 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| AIGH Capital Management LLC | 9.92% | 539,300 | 1.69M | Sep 29, 2024 |
| Sio Capital Management, LLC | 5.09% | 276,603 | 868.53K | Sep 29, 2024 |
| Sphera Funds Management Ltd. | 4.97% | 270,000 | 847.80K | Sep 29, 2024 |
| Nantahala Capital Management, LLC | 3.79% | 205,760 | 646.09K | Sep 29, 2024 |
| Vanguard Group Inc | 3.20% | 173,842 | 545.86K | Sep 29, 2024 |
| Stonepine Capital Management, LLC | 2.52% | 137,174 | 430.73K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.67% | 145,280 | 456.18K | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 0.53% | 28,562 | 89.68K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.47% | 25,275 | 79.36K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.13% | 7,197 | 22.60K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.11% | 5,963 | 18.72K | Oct 30, 2024 |
| Dimensional ETF Tr-Dimensional U.S. Targeted Value ETF | 0.09% | 5,083 | 15.96K | Jul 30, 2024 |